Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | RAD52 | P43351 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7998560 | 0.87 | RAD52 (0.45) | MAPTRAD52LMNADRD2KCNH2 | |
| SCHEMBL21626710 | 0.81 | LMNA (0.32) | LMNA | |
| SCHEMBL2079889 | 0.80 | DRD2 (0.44) | MAPTRAD52GAAGFERKDM4E | |
| SCHEMBL30986529 | 0.74 | DRD2 (0.32) | MAPTRAD52GAADRD2KCNH2 | |
| SCHEMBL27966943 | 0.73 | L3MBTL1 (0.36) | MAPTLMNA | |
| SCHEMBL15242530 | 0.72 | DRD3 (0.40) | MAPTKDM4ELMNADRD2 | |
| SCHEMBL20651757 | 0.72 | MITF (0.31) | SMN1; SMN2LMNA | |
| SCHEMBL3440728 | 0.72 | CYP2C19 (0.44) | MAPTGAAKDM4ELMNA | |
| SCHEMBL29520297 | 0.72 | CYP2C19 (0.44) | MAPTGAAKDM4ELMNA | |
| SCHEMBL11075570 | 0.71 | RAD52 (0.36) | MAPTRAD52GAAGFERKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | disclosed |
| WO-2017117447-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | MALT1, BCL9, BCL6 | ATAD2 3720/4885MAPT 82/4885RAD52 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.